Grass City 20% OFF

HENDERSON, NV / ACCESSWIRE / September 6, 2018 / A fascinating biotech firm we discovered PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in under two weeks time, the stock is still holding a substantial gain of 4435% as we speak. PPCB has a 52 week high of $0.77 which is still an absolutely massive increase from the currently trading price. PPCB is currently preparing for its Phase 1 Clinical Trial of its lead product PRP, which was granted FDA Orphan Drug Designation for Pancreatic cancer. If this is the first time you are hearing about PPCB, start doing your own research now. PPCB is an impressive biotech firm, with an intriguing patent portfolio. PPCB recently announced that it was selected to present at the 25th Annual NewsMakers in the biotech industry conference in New York City on September 7th, 2018. This is a major conference for such a micro biotech company like PPCB, and PPCB could receive significantly increased attention from the street in the coming weeks. Everyone that found PPCB before the upcoming conference has seen an incredible uptrend, and those that continue to find the company before its clinical trial could be in store for a historic ride.

Here are some other marijuana and biotech companies have seen explosive gains:

Propanc Biopharma, Inc. (PPCB), Aurora Cannabis, Inc.(OTCQX:ACBFF), Veristem, Inc. (VSTM),

Green Organic Dutchman Holdings Ltd.(TGODF), and ProQR Therapeutics N.V. (PRQR)

Propanc Biopharma, Inc. (PPCB)

Market Cap: $6.510M Share Price: $0.078

Propanc Biopharma Inc., a clinical stage biopharmaceutical company focusing on the development of new treatments for cancer. Patients who have solid tumors such as pancreatic, ovarian and colorectal cancers will be the specific focus. Interestingly enough, this company will begin to experience trials with human subjects. PRP is an FDA designated Orphan Drug, and by definition, it is a intravenous substance which is administered once a day. It is a combination of two pancreatic proenzymes: trypsinogen and chymotrypsinogen.

Propanc is currently readying for it’s first-in-human study, and PRP aims to prevent tumor recurrence and metastasis from solid tumors. As it is commonly known, most all cancers are solid tumors, and metastasis is the main cause of patient death from cancer. Unfortunately, millions of people died from cancer in 2012. A report by IMS Health states new therapies are causing the global oncology market to meet demand. This is expected to reach $150 billion by 2020. The Company’s focus on patient populations are pancreatic, ovarian and colorectal cancers. This represents an estimated combined market segment of $14 billion in 2020, according to GBI Research.

Veristem, Inc. (VSTM)

Market Cap: $392.6M Share Price: $4.33

CV Sciences (CVSI) has received more positive attention after it announced that it had appointed Joseph Maroon, MD, FACS to its Board of Directors. The Nevada-based company operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD, and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

Aurora Cannabis (ACBFF)

Market Cap: $6.301B Share Price: $6.68

Aurora Cannabis is receiving investor attention after announcing that its acquisition of Anandia Laboratories Inc. is now complete. The previously announced arrangement, under the provisions of the Business Corporations Act (British Columbia), means that among other things, Aurora has now acquired all of the issued and outstanding shares of Anandia in an all-share transaction.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eighty-three thousand two hundred dollars total by Regal Consulting, LLC, for PPCB. PPCB and Regal Consulting, LLC was given an opportunity to edit the information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty-eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States


SOURCE: ACR Communications LLC

Stock Symbols